OXFORDSHIRE, UNITED KINGDOM
Catalent recently acquired the Oxford, UK site and is investing up to $160 million (~£120 million) to complete the building of the facility and equip it with state-of-the-art drug substance capabilities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins and other advanced modalities.
The site will be integrated within Catalent Biologics’ existing network of facilities across Europe to offer an end-to-end solution from development and biomanufacturing to fill/finish and clinical supply services.
The new facility is located to the south of Oxford at the world-renowned Harwell Science and Innovation Campus, a leading site in the UK for science and technology, research breakthroughs, and home to more than 250 science and tech companies.
Size: 150,000+ ft² / ~14,000 m² (13 935.456m²)
Catalent Oxford Ltd
Harwell, Oxford, OX11 0GD
+44 (0)123 563 9600
Reach out to one of our experts to discuss any of our offerings or a specific solution for your project challenges.
We recognize talent is our most important asset. To explore a career with Catalent, visit our Careers Section to submit your resume.
CATALENT UK TAX STRATEGY
The purpose of this statement is to satisfy the UK legislative requirements of Schedule 19 Finance Act 2016 in relation to the publication of tax strategy insofar as it affects the UK companies in the Catalent group for the year ended 30 June 2023. Please download here.